p38delta/MAPK13 as a diagnostic marker for cholangiocarcinoma and its involvement in cell motility and invasion

International Journal of Cancer

Volumn 126, Issue 10, 2010, Pages 2353-2361

  Tan, Felicia Li Sher ^a,b   Ooi, Aikseng ^b,c   Huang, Dachuan ^b   Wong, Jing Chii ^b   Qian, Chao Nan ^b,c   Chao, Cora ^a   Ooi, London ^b   Tan, Yu Meng ^b   Chung, Alexander ^a   Cheow, Peng Chung ^a   Zhang, Zhongfa ^c   Petillo, David ^c   Yang, Ximing J ^d   Teh, Bin Tean ^b,c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cholangiocarcinoma; MAPK; p38; p38delta; SAPK

Indexed keywords

CYTOKERATIN 19; CYTOKERATIN 7; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 DELTA; UNCLASSIFIED DRUG; COLLAGEN; DIAGNOSTIC AGENT; LAMININ; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE 13; PROTEOGLYCAN; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; BILE DUCT; BILE DUCT CARCINOMA; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; GENE EXPRESSION; HEPATOBILIARY SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL CARCINOMA; METASTASIS; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY; STAINING; UPREGULATION; BILE DUCT TUMOR; CANCER INVASION; CELL MOTION; DIFFERENTIAL DIAGNOSIS; DRUG COMBINATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; IMMUNOLOGY; IMMUNOPRECIPITATION; INTRAHEPATIC BILE DUCT; METABOLISM; PATHOLOGY; PREDICTION AND FORECASTING; WESTERN BLOTTING;

ANTIGENS, NEOPLASM; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BLOTTING, WESTERN; CELL MOVEMENT; CHOLANGIOCARCINOMA; COLLAGEN; DIAGNOSIS, DIFFERENTIAL; DRUG COMBINATIONS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LAMININ; MITOGEN-ACTIVATED PROTEIN KINASE 13; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROTEOGLYCANS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 77951248825     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24944     Document Type: Article

References (25)

1. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002;37:806-813 (Pubitemid 35404220)
2. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33:1353-1357 (Pubitemid 32496970)
3. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, Khan SA, Elliott P, Thomas HC. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001;48:816-820
4. West J, Wood H, Logan RF, Quinn M, Aithal GP. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer 2006;94:1751-1758
5. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008;7:237-257 (Pubitemid 351895383)
6. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, Youssef BM, Klimstra D, Blumgart LH. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507-17; discussion 17-19
7. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002;51 Suppl 6:VI1-9.
8. Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology 2003;37:961-969
9. Johnson DE, Herndier BG, Medeiros LJ, Warnke RA, Rouse RV. The diagnostic utility of the keratin profiles of hepatocellular carcinoma and cholangiocarcinoma. Am J Surg Pathol 1988;12:187-197
10. Stroescu C, Herlea V, Dragnea A, Popescu I. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas. J Gastrointestin Liver Dis 2006;15:9-14. (Pubitemid 43845262)
11. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, Watson SJ, Meng F. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic acids research 2005;33:e175.
12. Tadlock L, Patel T. Involvement of p38 mitogen-activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line. Hepatology 2001;33:43-51. (Pubitemid 32016886)
13. Park J, Tadlock L, Gores GJ, Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 1999;30:1128-1133 (Pubitemid 29510848)
14. Yamagiwa Y, Marienfeld C, Tadlock L, Patel T. Translational regulation by p38 mitogen-activated protein kinase signaling during human cholangiocarcinoma growth. Hepatology 2003;38:158-166 (Pubitemid 36775807)
15. Tanaka S, Sugimachi K, Kameyama T, Maehara S, Shirabe K, Shimada M, Wands JR, Maehara Y. Human WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma. Hepatology 2003;37:1122-1129 (Pubitemid 36538689)
16. Meng F, Yamagiwa Y, Ueno Y, Patel T. Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol 2006;44:1055-1065 (Pubitemid 44308229)
17. Ben-Menachem T. Risk factors for cholangiocarcinoma. Eur J Gastroenterol Hepatol 2007;19:615-617
18. Agrawal S, Kuvshinoff BW, Khoury T, Yu J, Javle MM, LeVea C, Groth J, Coignet LJ, Gibbs JF. CD24 expression is an independent prognostic marker in cholangiocarcinoma. J Gastrointest Surg 2007;11:445-451
19. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007;1773:1358-1375 (Pubitemid 47125981)
20. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003;2:717-726 (Pubitemid 37361787)
21. Kim MS, Lee EJ, Kim HR, Moon A. p38 kinase is a key signaling molecule for HRas-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res 2003;63:5454-5461
22. Gum RJ, McLaughlin MM, Kumar S, Wang Z, Bower MJ, Lee JC, Adams JL, Livi GP, Goldsmith EJ, Young PR. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J Biol Chem 1998;273:15605-15610 (Pubitemid 28298174)
23. Eyers PA, Craxton M, Morrice N, Cohen P, Goedert M. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem Biol 1998;5:321-328 (Pubitemid 28309985)
24. Junttila MR, Ala-Aho R, Jokilehto T, Peltonen J, Kallajoki M, Grenman R, Jaakkola P, Westermarck J, Kahari VM. p38alpha and p38delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Oncogene 2007;26:5267-5279 (Pubitemid 47237627)
25. Schindler EM, Hindes A, Gribben EL, Burns CJ, Yin Y, Lin MH, Owen RJ, Longmore GD, Kissling GE, Arthur JS, Efimova T. p38delta Mitogen-activated protein kinase is essential for skin tumor development in mice. Cancer Res 2009;69:4648-4655